The bank noted that BioAge (BIOA) is running a Phase 2 study of azelaprag in combination with Zepbound, also known as ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

The IPO, which should see BioAge start trading on the Nasdaq today under the BIOA symbol, follows a $170 million Series D financing that completed in February and was earmarked for its phase 2 ...

BioAge’s star product is the anti-obesity drug Azelaprag, which is currently in Phase 2 trials. The drug is taken orally and ...

The company plans to release some phase 2 data next year, and, depending on the results, its stock could rise substantially. However, much like Recursion Pharmaceuticals, BioAge Labs remains an ...

This page features the latest news about the Bioage Labs stock. BioAge Labs director Enright buys $7.2 million in stock BioAge Labs, Inc. (NASDAQ:BIOA) has seen significant insider activity as ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

BioAge's main oral, small-molecule drug candidate ... and cash and equivalents of $159.1 million. Page 1 2 View All Ron Leuty covers biotech, life sciences, health and sports business.

Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical ... held in San Antonio from November 2–6, 2024. "Our preclinical data highlight the potential of azelaprag as a ...

In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify ...